Collegium Pharmaceutical (COLL) Competitors $29.58 -0.69 (-2.28%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends COLL vs. SVA, STML, NKTR, SPPI, EGRX, OGN, RYTM, IBRX, APLS, and MRUSShould you be buying Collegium Pharmaceutical stock or one of its competitors? The main competitors of Collegium Pharmaceutical include Sinovac Biotech (SVA), Stemline Therapeutics (STML), Nektar Therapeutics (NKTR), Spectrum Pharmaceuticals (SPPI), Eagle Pharmaceuticals (EGRX), Organon & Co. (OGN), Rhythm Pharmaceuticals (RYTM), ImmunityBio (IBRX), Apellis Pharmaceuticals (APLS), and Merus (MRUS). These companies are all part of the "medical" sector. Collegium Pharmaceutical vs. Sinovac Biotech Stemline Therapeutics Nektar Therapeutics Spectrum Pharmaceuticals Eagle Pharmaceuticals Organon & Co. Rhythm Pharmaceuticals ImmunityBio Apellis Pharmaceuticals Merus Collegium Pharmaceutical (NASDAQ:COLL) and Sinovac Biotech (NASDAQ:SVA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, community ranking, profitability and institutional ownership. Does the media favor COLL or SVA? In the previous week, Collegium Pharmaceutical had 5 more articles in the media than Sinovac Biotech. MarketBeat recorded 6 mentions for Collegium Pharmaceutical and 1 mentions for Sinovac Biotech. Collegium Pharmaceutical's average media sentiment score of 0.87 beat Sinovac Biotech's score of 0.00 indicating that Collegium Pharmaceutical is being referred to more favorably in the media. Company Overall Sentiment Collegium Pharmaceutical Positive Sinovac Biotech Neutral Is COLL or SVA more profitable? Collegium Pharmaceutical has a net margin of 14.78% compared to Sinovac Biotech's net margin of 0.00%. Collegium Pharmaceutical's return on equity of 104.67% beat Sinovac Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Collegium Pharmaceutical14.78% 104.67% 18.38% Sinovac Biotech N/A N/A N/A Which has more volatility and risk, COLL or SVA? Collegium Pharmaceutical has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, Sinovac Biotech has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500. Do analysts recommend COLL or SVA? Collegium Pharmaceutical presently has a consensus price target of $42.60, indicating a potential upside of 44.02%. Given Collegium Pharmaceutical's stronger consensus rating and higher probable upside, equities research analysts clearly believe Collegium Pharmaceutical is more favorable than Sinovac Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Collegium Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better valuation & earnings, COLL or SVA? Collegium Pharmaceutical has higher revenue and earnings than Sinovac Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCollegium Pharmaceutical$566.77M1.68$48.15M$2.3212.75Sinovac Biotech$448.27M1.44-$99.92MN/AN/A Does the MarketBeat Community believe in COLL or SVA? Collegium Pharmaceutical received 128 more outperform votes than Sinovac Biotech when rated by MarketBeat users. However, 67.99% of users gave Sinovac Biotech an outperform vote while only 65.25% of users gave Collegium Pharmaceutical an outperform vote. CompanyUnderperformOutperformCollegium PharmaceuticalOutperform Votes38565.25% Underperform Votes20534.75% Sinovac BiotechOutperform Votes25767.99% Underperform Votes12132.01% SummaryCollegium Pharmaceutical beats Sinovac Biotech on 13 of the 14 factors compared between the two stocks. Ad Darwin2024's Must-Watch Stocks!Welcome to a year of unparalleled opportunities! Dive into our exclusive guide, "9 Stocks Set to Soar," meticulously selected to elevate your portfolio in 2024. Step into 2024 with confidence and the right assets at your fingertips. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time. [Unlock Your Report Now] Get Collegium Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COLL vs. The Competition Export to ExcelMetricCollegium PharmaceuticalPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$953.96M$6.39B$5.07B$8.66BDividend YieldN/A8.08%5.10%4.06%P/E Ratio12.7510.92101.9217.45Price / Sales1.68245.131,198.0869.07Price / Cash2.8053.4940.9736.36Price / Book4.079.306.335.87Net Income$48.15M$154.14M$119.64M$225.66M7 Day Performance-8.02%-9.47%-5.13%-1.34%1 Month Performance-24.02%-7.30%-2.72%1.15%1 Year Performance17.71%28.21%31.08%24.02% Collegium Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COLLCollegium Pharmaceutical4.1071 of 5 stars$29.58-2.3%$42.60+44.0%+17.8%$953.96M$566.77M12.75210SVASinovac BiotechN/A$6.47flatN/AN/A$644.67M$448.27M0.003,261High Trading VolumeSTMLStemline TherapeuticsN/A$11.83flatN/A+0.0%$621.21M$43.22M-7.4492NKTRNektar Therapeutics4.2039 of 5 stars$1.37-2.1%N/A+112.0%$252.19M$93.16M-1.63220SPPISpectrum PharmaceuticalsN/A$1.03flatN/AN/A$211.41M$10.11M-2.8686Analyst ForecastEGRXEagle Pharmaceuticals1.1294 of 5 stars$0.85flatN/A-92.5%$11.04M$316.61M0.00134Analyst ForecastNews CoverageGap UpOGNOrganon & Co.4.7935 of 5 stars$16.08+0.2%N/A+37.3%$4.14B$6.41B3.1910,000Ex-DividendNews CoveragePositive NewsRYTMRhythm Pharmaceuticals3.7757 of 5 stars$65.58-2.6%N/A+73.2%$4.03B$77.43M-15.15140Insider SellingHigh Trading VolumeIBRXImmunityBio0.7014 of 5 stars$5.45-2.2%N/A+9.8%$3.80B$1.31M-5.62590APLSApellis Pharmaceuticals4.501 of 5 stars$29.58-1.3%N/A-45.1%$3.68B$396.59M-14.57702MRUSMerus1.88 of 5 stars$52.96-2.8%N/A+95.7%$3.63B$43.95M-13.4137Positive News Related Companies and Tools Related Companies SVA Competitors STML Competitors NKTR Competitors SPPI Competitors EGRX Competitors OGN Competitors RYTM Competitors IBRX Competitors APLS Competitors MRUS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:COLL) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Collegium Pharmaceutical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Collegium Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free COLL Stock Alerts